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Abstract
Objective—To identify a biomarker profile associated with tumor response to chemoradiation
(CRT) in locally advanced rectal cancer.
Background—Rectal cancer response to neoadjuvant CRT is variable. While some patients have
a minimal response, others achieve a pathologic compete response (pCR) and have no viable
cancer cells in their surgical specimens. Identifying biomarkers of response will help select
patients more likely to benefit from CRT.
Methods—This study includes 132 patients with locally advanced rectal cancer treated with
neoadjuvant CRT followed by surgery. Tumor DNA from pre-treatment tumor biopsies and
control DNA from paired normal surgical specimens was screened for mutations and
polymorphisms in 23 genes. Genetic biomarkers were correlated with tumor response to CRT
(pCR versus non-pCR), and the association of single or combined biomarkers with tumor response
was determined.
Results—Thirty-three out of 132 (25%) patients achieved a pCR and 99 (75%) patients had non-
pCR. Three individual markers were associated with non-pCR; KRAS mutation (p = 0.0145),
CCND1 G870A (AA) polymorphism (p = 0.0138), and MTHFR C677T (TT) polymorphism (p =
0.0120). Analysis of biomarker combinations revealed that none of the 27 patients with both p53
and KRAS mutations had a pCR. Further, in patients with both p53 and KRAS mutations or the
CCND1 G870A (AA) polymorphism or the MTHFR C677T (TT) polymorphism (n = 52) the
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association with non-pCR was further strengthened; 51 out of 52 (98%) of patients were non-pCR.
These biomarker combinations had a validity of >70% and a positive predictive value of 97%–
100%, predicting that patients harboring these mutation/polymorphism profiles will not achieve a
pCR.
Conclusions—A specific biomarker profile is strongly associated with non-pCR to CRT and
could be used to select optimal oncologic therapy in rectal cancer patients.
Introduction
In recent years combined chemotherapy and radiation therapy (CRT) before total mesorectal
excision (TME) has become the standard treatment for patients with locally advanced rectal
cancer. This approach provides excellent tumor control and long-term survival1–4 but it is
associated with measurable mortality, significant morbidity, and long-lasting sequelae that
may permanently impair quality of life.5–8 It is now evident that preoperative CRT is not
equally beneficial for all rectal cancer patients. Some patients have a minimal response to
CRT, whereas others have no detectable cancer cells in the primary tumor location or in
regional lymph nodes in the surgical specimen. Patients with such a pathologic complete
response (pCR) have a better prognosis compared to non-pCR patients.9–15 If tumor
response could be predicted before surgery, patients with resistant tumors could be spared
CRT-related toxicity and expense. Furthermore, patients likely to achieve a pCR could
potentially avoid the morbidity and functional consequences of TME. The benefit for these
patients in terms of quality of life would be significant. Unfortunately, identifying
responders and non-responders to CRT before surgery remains a challenge.
While tumor response to CRT depends on treatment-related factors, such as radiation dose
and the type of chemotherapy administered, tumor biology appears to play the most
important role in governing rectal cancer response to CRT.16,17 The search for molecular
predictors of rectal cancer response to CRT has been an active area of research because such
biomarkers could profoundly affect the clinical management of rectal cancer patients and
influence the use of organ-preserving treatment strategies such as local excision or
observation. Many studies have reported biomarkers of response to CRT, focusing on gene
expression, mutations, and polymorphisms;16–22 and although select genes or gene
combinations have been identified as potential surrogates of response, none have been
validated and incorporated into clinical practice.
In this study we screened a series of 132 patients who were treated in a prospective rectal
cancer trial for mutations and polymorphisms in 23 genes with previously reported roles in
the pathogenesis of colorectal cancer. Our objective was to determine whether these
molecular alterations alone or in combination were associated with response to CRT.
Patients and methods
Patient eligibility
Patients with clinical American Joint Committee on Cancer (AJCC)23 stage II (T3-4, N0) or
stage III (any T, N1-2) invasive adenocarcinoma of the rectum with a distal tumor border
within 12 cm of the anal verge were enrolled in the Timing of Rectal Cancer Response to
Chemoradiation study, a multi-institutional prospective clinical trial investigating the effect
of increasing the CRT-to-surgery time interval, and adding modified FOLFOX-6
chemotherapy (mFOLFOX-6) during the interval period (ClinicalTrials.org Identifier:
NCT00335816). This trial was designed as a series of sequential Phase II trials or study
groups (SGs), each with a progressively longer CRT-to-surgery interval and increasing
cycles of preoperative mFOLFOX-6. This study was approved by an Institutional Review
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Board (IRB) at each participating institution as well as a central IRB, and informed written
consent was obtained from each patient prior to enrollment in the trial. Patients included in
the present study were pooled from SG1 (n = 52), SG2 (n = 58) and SG3 (n = 22). Further
details of patient eligibility for this trial are presented elsewhere.24
Treatment protocol
Patients in all SGs were treated with CRT; 5-Fluorouracil (FU) 225 mg/m2/day for 7 days in
continuous infusion, and a total of 50.4Gy radiation. Patients in SG1 underwent TME an
average of 6 weeks after completing CRT (standard of care). Following CRT, patients in
SG2 and SG3 with signs of stable disease or disease progression compared with baseline
staging had surgery without further delay. All other patients received 2 and 4 cycles of
additional chemotherapy (mFOLFOX-6), respectively; leucovorin 200 mg/m2 or 400 mg/m2
plus oxaliplatin 85 mg/m2 by 2h infusion, followed by bolus of 5-FU 400 mg/m2 and a 46h
infusion of 5-FU 2,400 mg/m2. Patients in SG2 and SG3 underwent TME an average of 11
and 16 weeks after completing CRT. The clinical outcomes for these patients are presented
elsewhere.24
Tumor response to CRT
Pathologic complete response was defined as the complete absence of tumor cells from the
rectal wall and regional lymph nodes by hematoxylin and eosin staining under microscopy.
Tumor pathology was assessed by two independent pathologists and graded according to the
recommendations of the AJCC.23 For the purposes of the study, response was classified as
either pCR or non-pCR based on the above criteria.
Sample preparation and molecular analysis
Tumor DNA from pre-treatment tumor biopsies and control DNA from paired normal
surgical specimens for all patients was extracted as follows: 10–20 slides per patient sample
from formalin-fixed paraffin-embedded (FFPE) tumor biopsies and normal tissues were de-
paraffinized, hydrated, and stained with 0.2% methylene blue. A 27.5 gauge needle was then
used to manually micro-dissect cells under inverted microscopy. Genomic DNA was
extracted using the QIAamp DNA FFPE Tissue kit (Qiagen Inc., Valencia, CA) according to
manufacturer’s instructions with the following modifications; an extension of digestion time
at 56°C from 1 hour to 48 hours and the addition of three 20 μl aliquots of Proteinase-K at 4,
20, and 28 hours during digestion. DNA was then quantified by measuring absorbance at
260nm.
PCR analysis and Sanger sequencing
Gene mutations and polymorphisms were screened by standard polymerase chain reaction
(PCR) followed by Sanger sequencing (primer sequences shown in Supplementary Table 1).
PCR reactions consisted of 10 mM Tris-HCl (pH: 8.3), 50 mM KCl, 1.5 mM MgCl2, 5 mM
primers, 200 mM dNTP, 0.1 μg/ml BSA, 0.5 U Amplitaq Gold (Applied Biosystems, Foster
City, CA) plus 2 μl of tumor or control DNA in a total volume of 25 μl. Cycling conditions
were 94°C for 30 seconds, annealing for 30 seconds (specific temperatures shown in
Supplementary Table 1), and 72°C for 1 minute, for a total of 40–45 cycles. An initial
denaturation at 94°C for 10 minutes and a final extension at 72°C for 7 minutes were used.
Two independently extracted DNA samples for each patient biopsy or surgical specimen
were simultaneously amplified with a negative control (H20). 2 μl of each PCR reaction was
analyzed in a 2% agarose gel to verify the presence of the expected amplified product. All
sequencing reactions were carried out in both sense and antisense directions with PCR
primers by Sanger sequencing and all mutations and polymorphisms were confirmed by
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sequencing two independently-derived PCR products. Somatic mutations and
polymorphisms were verified by comparison to paired normal surgical-specimen controls.
Statistical analysis
Patient characteristics—To determine differences in clinical and pathological features
between pCR and non-pCR patients, the Mann-Whitney U test was used for comparing
means of continuous variables between groups and the two sided Fisher’s Exact test and chi-
square test were used for testing the significance of differences in the distributions of
categorical variables.
Characterizing biomarkers—For genes which could be classified as wild-type or
mutant, 2 × 2 analysis tables were constructed and genes were tested for association with
tumor response using Fisher’s Exact test. For genes with multiple polymorphisms, each
polymorphism was partitioned into three separate binary variables comparing a single allelic
variation to the remaining combined alleles.
An exhaustive combinatorial analysis was performed to determine the association of each
marker or combinations of markers with tumor response. All logical combinations were used
(i.e., logical operator AND, logical operator OR) among the binary variables including 1, 2,
3 or 4 markers at a time. Over 3 × 106 combinations were tested. This combinatorial
approach allowed us to determine whether patients fail to respond if they carry at least one
biomarker (OR) or whether the presence of numerous simultaneous biomarkers (AND/OR)
are required to predict non-pCR.
False discovery rate (FDR) was used to control for multiple comparisons.25 Markers that
remained significant after FDR adjustment were internally cross-validated using 100
iterations, randomly selecting 70% of the subjects for “training” and 30% of the subjects for
“testing”. The Monte Carlo-based CVLR in SAS cross-validation algorithm was used.26
Finally the 2 × 2 tables and logistic regression scores were used to calculate the area under
the curve (AUC) of the receiver operating characteristic (ROC) curve, and the sensitivity,
specificity, and positive and negative predictive values of the molecular markers.
Results
Patient characteristics and tumor response
A total of 132 patients (58 in SG1, 52 in SG2, and 22 in SG3) were included in the analysis.
Patient demographics stratified by pCR status for all patients are shown in Table 1. Overall,
33 out of 132 (25%) patients achieved a pCR. The 99 remaining non-pCR patients (75%)
showed either a pathologic partial response (pPR) or had stable disease. No patients had
disease progression. Seventeen (29%) patients in SG1 achieved a pCR, 10 (19%) in SG2 and
6 (27%) in SG3 (Table 1). There were no significant differences in tumor response between
SGs, and there were no significant differences in clinical or pathological factors between
pCR and non-pCR patients, or between SGs.
Individual biomarker analysis
Tumor DNA from pre-treatment tumor biopsies and control DNA from paired normal
surgical specimens for all patients was screened for mutations and polymorphisms in 23
genes (Supplementary Table 1). Following screening and statistical analysis, 3 biomarkers
were found to associate individually with non-pCR (Table 2). v-Ki-ras2 Kirsten rat sarcoma
viral oncogene homolog (KRAS) mutations were more common in non-pCR patients
compared to patients with a pCR (49% versus 24%, p = 0.0145), while the cyclin D1
(CCND1) G870A and methylenetetrahydrofolate reductase (NAD(P)H) (MTHFR) C677T
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polymorphisms were also associated with non-pCR. Specifically, patients with the AA
polymorphism at the 870 locus of the CCND1 gene were significantly less likely to achieve
a pCR compared to patients who carried either the GA or GG alleles at the same location (p
= 0.0138). Of the total number of patients who carried the AA polymorphism in our patient
population (19 out of 132), 18 of 19 (95%) did not achieve a pCR. None of the patients that
carried the TT polymorphism at the 677 locus of the MTHFR gene (14 out of 132) achieved
a pCR (p = 0.0120).
Of interest, mutations in tumor protein p53 (p53), v-raf murine sarcoma viral oncogene
homolog B1 (BRAF), catenin (cadherin-associated protein), beta 1, 88kDa (CTNNB1) and
phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA), each previously reported
to play a role in the pathogenesis of colorectal cancer, were not significantly associated with
pCR in our patient population as stand-alone biomarkers (Table 2). No other single gene
mutation or polymorphism was significantly associated with tumor response (Supplementary
Table 2).
Combination biomarker analysis
Next, mutation/polymorphism combinations for all molecular alterations were tested up to
the order of 4 simultaneous markers. Approximately 3-million different combinations were
tested and screened with FDR correction to the p-value. Following analysis, 6 different
biomarker combinations were identified as both sufficiently prevalent in our patient
population for meaningful validation and statistically associated with tumor response (pCR
versus non-pCR) in a synergistic fashion (Table 3). The majority of these biomarker
combinations included mutations in both p53 and KRAS (5 out of 6). The significance of this
molecular profile is reflected in our patient population, where 27 out of 132 patients had
concurrent KRAS and p53 mutations and none had a pCR to CRT. Further, in patients with
both p53 and KRAS mutations or the CCND1 G870A (AA) polymorphism (n = 43) or the
MTHFR C677T (TT) polymorphism (n = 52) the association with non-pCR was further
strengthened (Table 3). When either polymorphism was added to the molecular profile, 51
out of 52 (98%) patients failed to achieve a pCR to CRT.
Validation of predictive biomarker profiles
The four most prevalent biomarkers (KRAS mutation; p53 mutation; CCND1 G870A [AA]
polymorphism; MHTFR C677T [TT] polymorphism) based on a significant association with
non-pCR individually or in combination were chosen for further validation to determine
their value for predicting non-pCR. Following internal validation, each biomarker
combination analyzed had a validity of over 70% (Table 4). All combination sets had similar
specificity and positive predictive values (97%–100%). The combination of all four markers
- p53 and KRAS mutation, or the CCND1 G870A (AA) polymorphism, or the MTHFR
C677T (TT) polymorphism - resulted in the highest AUC of the ROC curve (AUC = 0.74)
and the highest sensitivity (52%) predicting that patients with this mutation/polymorphism
profile will not achieve a pCR to CRT.
Discussion
In the current study we identified gene mutations and polymorphisms that are individually
associated with failure to achieve a pCR to CRT. We also found that when combined, these
mutations and polymorphisms synergistically identify a subset of rectal cancer patients who
do not develop a pCR in response to CRT with a high degree of accuracy.
Our results have immediate clinical relevance given that achieving a complete clinical
response to CRT may be followed by an organ preservation approach such as local excision
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or observation in select patients with rectal cancer. Indeed a number of collaborative groups
are already exploring the feasibility of these approaches. The American College of Surgeons
Oncology Group (ACOSOG) recently completed a trial of CRT before local excision for
T2N0 rectal cancer patients27 and a wait-and watch approach has been attempted at a small
number of institutions.28 The deferral of surgery for rectal cancer patients who develop a
clinical complete response (cCR) to CRT is also being studied prospectively by the National
Cancer Research Network in collaboration with the Pelican Cancer Foundation in the United
Kingdom. However, a cCR does not always correlate with a pCR and patients with a cCR
after CRT may still have cancer cells in their surgical specimens. Our results show that
biomarker profiling could help identify a subset of patients highly unlikely to develop a pCR
to CRT and consequently help direct these patients away from organ preservation treatment
strategies and towards clinically beneficial therapies such as TME.
KRAS is a key component of the mitogen activated kinase (MAPK) pathway that is activated
by cell surface receptors such as epidermal growth factor receptor (EGFR). These signals
are then transduced to the nucleus where they phosphorylate and activate transcription
factors leading to changes in gene expression.29,30 Mutant variants in the KRAS gene result
in constitutive activation of its encoded protein, resulting in persistent activation of the
MAPK pathway.29,30 KRAS is mutated in over a third of colorectal cancers and experimental
evidence has shown that KRAS mutations can be found in the earliest tumor stage, and that
once acquired, these mutations are preserved throughout the natural history of the
tumor.31,32 Although previous studies on the prognostic value of KRAS mutation in patients
with colorectal cancer have reported different results,33 the recent discovery that KRAS
mutation is a strong predictor of colorectal cancer response to the anti-EGFR monoclonal
antibodies Cetuximab and Panitumumab34,35 has further established this gene as an
important biomarker in colorectal cancer. Indeed KRAS mutation status is now routinely
checked in every rectal cancer patient for potential candidacy of anti-EGFR therapy.36
Few studies have evaluated KRAS as a biomarker for tumor response in rectal cancer
patients treated with CRT and TME. Luna-Perez, et al. described a series of rectal cancer
patients treated with preoperative CRT and reported that tumors with wild-type KRAS were
more likely to respond to CRT than tumors with mutant KRAS.37 However, these results
should be interpreted with caution due to their small sample size, low rate of pCR, sub-
standard radiotherapy, and the use of radiated cancer tissue for KRAS analysis. Bengala, et
al. also found that tumors with wild-type KRAS were more likely to respond to CRT
compared to mutant KRAS (37% versus 11%) in 39 patients treated with Cetuximab and
CRT.38 Our data confirm these observations indicating that rectal cancers with wild-type
KRAS are more likely to develop a pCR to 5-FU based CRT compared to tumors with
mutant KRAS. Mutant KRAS may therefore be a biomarker for non-pCR in rectal cancer
patients treated with CRT, with or without EGFR-inhibitors. However, other studies have
reported contradictory results.39,40 Erben, et al. found no correlation between KRAS
mutation and tumor down-staging in 57 rectal cancer patients treated with Cetuximab,
Irinotecan and Capecitabine in combination with pelvic irradiation.39 Similarly, Gaedcke, et
al. found no correlation between KRAS mutation and tumor down-staging in rectal cancer
patients treated with 5-FU and Oxaliplatin during radiation.40 However, these were smaller
series, utilizing different radio-sensitizing drugs, and using different definitions of tumor
response.
The CCND1 gene encodes the cyclin D1 protein which is a key regulator of the cell cycle,
promoting the transition from G1 to S phase and committing the cell to division and
proliferation.41 CCND1 expression is elevated in many types of cancers and its expression is
regulated at multiple levels including transcription, translation and protein stability and
degradation.41,42 Polymorphisms within CCND1 contribute to its regulation and possibly to
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its oncogenic potential. Of over 100 reported CCND1 polymorphisms, the GA
polymorphism at locus 870 has received the most attention. This polymorphism is located at
the exon 4/intron 4 boundary and has been linked to alternative gene splicing. The G allele
codes for the optimal splicing which produces the canonical form, termed cyclin D1a, while
the A allele constrains exon 4 excision and allows translation into intron 4 resulting in a
truncated cyclin D1b transcript that lacks the sequences required for degradation. The
increase in the half-life in this variant form of CCND1 is consistent with an increase in cell
proliferation, and the A allele has been associated with increased risk and advanced tumor
stage in colorectal cancer, and a poor prognosis in a variety of cancers.43 Li, et al. recently
reported that cyclin D1a is also important to elicit the DNA damage response (DDR) that
may result in DNA repair.44 Our findings, that patients homozygous for the A allele are less
likely to respond to CRT, are consistent with the increased cell proliferation and reduced
contribution to DDR associated with cyclin D1b. However, other series have reported
contradictory results. Ho-Pun-Cheung, et al. reported better tumor response and lower risk
of local recurrence associated with the AA allele among 65 patients with rectal cancer
treated with preoperative radiotherapy.45 However in this smaller series, patients did not
receive sensitizing chemotherapy, and response was based on histological tumor regression
rather than on pCR.
Exposure of cells to DNA-damaging agents, such as ionizing radiation and
chemotherapeutic drugs, elicits a complex set of acute cellular responses that involve the
coupling of cell cycle arrest, DNA repair, and apoptosis. The central component of these
responses is the product of the p53 gene, which modulates transcription of responsive genes
involved in temporary or permanent growth arrest or apoptosis. Inactivation of p53
contributes to cellular resistance to DNA-damaging agents in vitro and in vivo.46,47 Over
50% of colorectal cancers harbor p53 mutations. Most of them are missense mutations,
leading to the synthesis of a stable but inactive protein that accumulates in the nucleus of
tumor cells. A number of studies have evaluated p53 mutations as predictors of response in
rectal cancer patients treated with neoadjuvant therapy.48–50 While some studies found an
association between mutant p53 and tumor response to radiation,48,49 other studies have not
confirmed this association.50 Our results concur with those series which found that mutant
p53 alone is not associated with tumor response to CRT. However, we found that mutant
p53 becomes a predictive biomarker of non-pCR when present in cancer cells harboring a
KRAS mutation. In these cells, the combined mutation/polymorphism profile of these
biomarkers may synergistically promote increased proliferation (KRAS mutation) coupled
with tumor resistance to radiation and chemotherapy (p53 mutation) resulting in non-pCR.
The MTHFR gene codes for an enzyme that catalyzes conversion of 5,10-MTHF to 5-
MTHF, the dominant circulating form of folate. 5,10-MTHF is used for the thymidylase
synthase (TS)-catalyzed conversion of deoxyuridylate to deoxythymidylate, important for
DNA synthesis. A C-to-T transition in codon 677 of the MTHFR gene results in a genotypic
variant associated with decreased enzyme activity.51 Reduced MTHFR activity may increase
the amount of 5,10-MTHF available for the TS enzyme, and increase the effect of TS
inhibitors such as 5-FU, in individuals carrying this polymorphism. While there are mixed
results from studies investigating the effect of the MTHFR C677T polymorphism on
colorectal cancer response to 5-FU,52–54 two studies suggest this polymorphism does affect
rectal cancer response.53,54 Terrazzino, et al. found that the likelihood of response for 122
patients treated with fluoropyrimidine-based CRT and surgery was higher among patients
homozygous for the C allele compared to carriers of the T allele.53 Similarly, Cecchin, et al.
found that the T allele was associated with lower response rates in a series of 238 rectal
cancer patients treated with fluoropyrimidine-based chemotherapy.54 Our study found
similar resistance to CRT associated with MTHFR C677T. Despite methodological
differences between these two studies and our trial (both used radio-sensitizers in addition to
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fluoropyrimidines, defined response using tumor regression grade (TRG) rather than pCR,
and used different CRT-to-surgery intervals), their combined results suggest that the
MTHFR C677T (TT) polymorphism is associated with non-pCR to CRT.
There are a number of limitations to our study that warrant consideration. First, the sample
size is relatively small and the study endpoint, pCR, occurred in only 25% of patients.
Furthermore, while we used a common statistical cross-validation method, which has been
applied extensively to biomarker-validation studies,55 a larger independent series with more
pCR and non-pCR patients will be important to validate these results. To address this we are
continuing to collect specimens from additional patients in SG1–SG3 to further validate our
results as well as extending our studies to an independent patient cohort. Second, although
this is a prospective study with a homogenous patient population, the treatment regimen
varied between the three SGs in both the use of adjuvant chemotherapy and the CRT-to-
surgery interval. Third, the tissue used to extract normal control DNA was obtained from the
proximal resection margin of the surgical specimens. This tissue is usually outside the
radiation field and it is unlikely that it received the full dose of radiation, but it was exposed
to chemotherapy. While we have recently shown that mutations in KRAS and p53 remain
largely unchanged in rectal cancer after CRT,56 the possibility of mutations arising due to
treatment can not be totally excluded.
In conclusion, we have identified a biomarker profile that is associated with tumor resistance
to CRT, evidenced by a lack of pCR. These findings are important because they help
identify a subset of patients with rectal cancers who most likely will not respond to CRT and
therefore should not be considered as candidates for organ preservation following CRT.
Supplementary Material
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Table 1
Patient demographics and tumor characteristics overall and stratified by study group
Demographic/Characteristic pCR (n=33) Non-pCR (n=99)
Age, years * 56 (32–80) 57 (26–87)
Female 13 (39%) 42 (42%)
Race
 Asian/Pacific Islander 3 (9%) 4 (4%)
 Black 2 (6%) 2 (2%)
 White 26 (79%) 85 (86%)
 Unknown 2 (6%) 8 (8%)
Clinical T stage
 T2 5 (15%) 5 (5%)
 T3 27 (82%) 90 (91%)
 T4 0 (0%) 2 (2%)
 Tx 1 (3%) 2 (2%)
Clinical N stage
 N0 4 (12%) 24 (24%)
 N1 26 (79%) 66 (67%)
 N2 1 (3%) 6 (6%)
 Nx 2 (6%) 3 (3%)
Clinical AJCC stage
 II 4 (12%) 24 (24%)
 III 27 (82%) 73 (74%)
 Unknown 2 (6%) 2 (2%)
Study group (SG) †
 SG1 (n=58) 17 (29%) 41 (71%)
 SG2 (n=52) 10 (19%) 42 (81%)
 SG3 (n=22) 6 (27%) 16 (73%)
*
Median (Range).
†
SG1 had surgery 6 weeks after the completion of CRT (standard of care); SG2 had surgery 11 weeks after the completion of CRT, and had 2
cycles of modified FOLFOX-6 during the waiting period; SG3 had surgery 16 weeks after the completion of CRT, and had 4 cycles of modified
FOLFOX-6 during the waiting period. Abbreviations: pCR – Pathologic complete response; AJCC – American Joint Committee on Cancer; SG –
Study group.
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Table 2
Gene mutations and polymorphisms individually associated with non-PCR
Mutation/Polymorphism Prevalence in patient population (n=132) pCR (n=33) Non-pCR (n=99) p-value
KRAS 57 (43%) 8 (24%) 49 (49%) 0.0145 *
BRAF 1 (1%) 1 (3%) 0 (0%) 0.2500
p53 75 (57%) 16 (48%) 59 (60%) 0.3124
PIK3CA 40 (30%) 12 (36%) 28 (28%) 0.3898
CTNNB1 1 (1%) 0 (0%) 1 (1%) 1.0000
CCND1 G870A 0.0138 *
 AA 19 (14%) 1 (3%) 18 (18%)
 GA 68 (52%) 23 (70%) 45 (45%)
 GG 45 (34%) 9 (27%) 36 (36%)
MTHFR C677T 0.0120 *
 CC 60 (45%) 18 (55%) 42 (42%)
 TC 58 (44%) 15 (45%) 43 (43%)
 TT 14 (11%) 0 (0%) 14 (14%)
*
Statistically significant at 0.05. Abbreviations: pCR – Pathologic complete response.
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